Pfizer Ventures co-launches $16m rare drug accelerator
This article was originally published in Scrip
Executive Summary
A new rare disease drug accelerator has launched in the US with $16 million in financing and big plans to spin-out up to five new companies in the next four years, developing orphan-focused products.